Trial Profile
A drug utilisation safety and efficacy study of fingolimod in patients with multiple sclerosis in real world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms VIRGILE
- 11 Feb 2022 Primary endpoint (Changes in the annualised relapse rate) has been met, as per results published in the Neurology and Therapy.
- 11 Feb 2022 Results published in the Neurology and Therapy
- 11 Feb 2022 Status changed from active, no longer recruiting to completed, as per results published in the Neurology and Therapy.